News | Radiopharmaceuticals and Tracers | March 16, 2017

Fluciclovine PET/CT Improves Radiotherapy Targeting for Recurrent Prostate Cancer

New study finds PET/CT in treatment planning leads to significant differences in target volumes

PET/CT, recurrent prostate cancer, fluciclovine F-18, Emory University

CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.

March 16, 2017 — The featured clinical investigation article of the March 2017 issue of the Journal of Nuclear Medicine demonstrates that the positron emission tomography (PET) radiotracer fluciclovine (fluorine-18; F-18) can help guide and monitor targeted treatment for recurrent prostate cancer, allowing for individualized, targeted therapy.

"This is the first study of its kind demonstrating changes in post-surgery radiotherapy target design with advanced molecular imaging in recurrent prostate cancer, with no demonstrated increase in early radiotherapy side effects," explained Ashesh B. Jani, M.D., of the Winship Cancer Institute of Emory University, Atlanta.

According to the American Cancer Society, one in seven men will develop prostate cancer in his lifetime. In 2017, more than 161,000 new diagnoses of prostate cancer are expected in the U.S., and about 26,730 deaths from the disease are anticipated.

For the study, 96 patients were enrolled in a clinical trial of radiotherapy for recurrent prostate cancer after prostatectomy. All patients underwent initial treatment planning based on results from conventional abdominopelvic imaging with computed tomography (CT) or magnetic resonance imaging (MRI). Forty-five of the patients then underwent treatment-planning modification (better defining the tumor-targeted area) after additionally undergoing abdominopelvic F-18-fluciclovine PET/CT. No increase in toxicity was observed with this process.

The Emory researchers determined that the inclusion of F-18-fluciclovine PET information in the treatment planning process leads to significant differences in target volumes. It did result in higher radiation dose delivered to the penile bulb, but no significant differences in bladder or rectal radiation dose, or in acute genitourinary or gastrointestinal toxicity.

These are preliminary results in a three-year study, which hypothesizes that there will be an increase in disease-free survival for patients in the F-18-fluciclovine-modified treatment group over those in the standard treatment group.

This study could have implications beyond prostate cancer, Jani pointed out. "Our methodology is readily applicable to other novel imaging agents, and it may potentially facilitate improvement of cancer control outcomes," he said.

Authors of the article "Impact of Fluciclovine (18F) PET on Target Volume Definition for Post-Prostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial" include Jani, Eduard Schreibmann, Peter J. Rossi, Joseph Shelton, Karen Godette, Peter Nieh, Viraj A. Master, Omer Kucuk, Mark Goodman, Raghuveer Halkar, Sherrie Cooper, Zhengjia Chen, and David M. Schuster, Emory University, Atlanta, Georgia.

This research was sponsored by the National Institutes of Health (R01 CA169188) and Blue Earth Diagnostics Ltd.

For more information: www.jnm.snmjournals.org

References

Jani, A.B., Schreibmann, E., Rossi, P.J., Shelton, J., et al. "Impact of Fluciclovine (18F) PET on Target Volume Definition for Post-Prostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial," Journal of Nuclear Medicine. Published online Sept. 8, 2016. DOI: 10.2967/jnumed.116.176057

Related Content

high-intensity focused ultrasound, HIFU, prostate tissue ablation, after radiotherapy, EDAP TMS SA, Ablatherm, British Journal of Urology International study
News | Focused Ultrasound Therapy | March 29, 2017
EDAP TMS SA announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic HIFU (high-intensity...
News | Radiopharmaceuticals and Tracers | March 29, 2017
Advanced Accelerator Applications S.A. announced that its product NETSPOT (gallium Ga-68 dotatate) has been included in...
lung cancer recurrence, biomarker blood test, CT scans, 2017 Multidisciplinary Thoracic Cancers Symposium, clinical study
News | Lung Cancer | March 28, 2017
Results from a prospective clinical trial showed a blood test looking at specific biomarkers was able to detect lung...
VERT, virtual environment radiotherapy, radiation therapy, patient anxiety, Thomas Jefferson University study
News | Radiation Therapy | March 27, 2017
March 27, 2017 — Radiation therapists and physicians know that education can reduce anxiety before radiation treatmen
proton therapy, recurrent lung cancer, clinical study, IMPT, 2017 Multidisciplinary Thoracic Cancers Symposium
News | Proton Therapy | March 24, 2017
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for...
Karmanos Cancer Institute, UroNav Fusion Biopsy System, prostate cancer
News | Biopsy Systems | March 23, 2017
March 23, 2017 — Urology specialists at the Barbara Ann Karmanos Cancer Institute (Detroit) have begun using the UroN
News | Prostate Cancer | March 22, 2017
Profound Medical Corp. announced that it has successfully completed the first sale of a TULSA-PRO system in Finland to...
lung cancer, radiation therapy, immune checkpoint inhibitors, 2017 Multidisciplinary Thoracic Cancers Symposium, clinical study
News | Lung Cancer | March 22, 2017
An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors (ICPIs)...
diffusion weighted MRI, children, traumatic brain injury, TBI recovery, Neurology journal study
News | Magnetic Resonance Imaging (MRI) | March 21, 2017
A new imaging biomarker may help predict which children will take longer to recover from a traumatic brain injury (TBI...
SBRT, stereotactic body radiation therapy, early-stage lung cancer, patients 80 and older, 2017 Multidisciplinary Thoracic Cancers Symposium, study
News | Stereotactic Body Radiation Therapy (SBRT) | March 20, 2017
Patients in their 80s and 90s who have early-stage lung cancer but cannot undergo an operation can be treated safely...
Overlay Init